Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: sysiphus who wrote (63299)	11/25/2025 9:19:14 AM
From: erickerickson	Respond to of 63318

GLUE: The Novartis deal was announced something like 2 months ago, which produced a nice spike, closed at $6.93 up from $4.81 the previous trading day. But that was over $8 ago and I'm wondering about the continued upside since then. Having all that cash is certainly very, very nice I agree. "Beating estimates" doesn't mean much for a company at this stage so I discount that. Perhaps the Novartis deal brought GLUE to people's attention. The stock was trading around 300K shares/day prior to the announcement, which could put it under the radar. When the deal was announced, it traded over 30M shares. (yes, a 100x multiple. That's not a tyop) and the volume has stayed higher than pre-Novartis (2-3x multiple maybe). So I don't really have a clue. Avoro sold their entire position (reported 11/14). For once I'm out-performing them ;) I'll pat myself on the back until I keep holding it and it drops to $1... All that said, I'm enjoying the ride. And just to add to the fun, yesterday it was down something like 15% pre-market when I checked. This morning it's up 2%. Which is just more evidence that, absent IGN, pre-and-post-market is meaningless...